As stem cell banking becomes more visible in the consumer space, primary care physicians and general practitioners are increasingly fielding patient questions they did not seek out. The physician’s role here is not to sell banking; it is to keep the conversation compliant, document it, and direct the patient to appropriate resources. Handled well, this is a routine clinical exchange with a clear documentation footprint. Handled poorly, it can create an FTC substantiation problem or leave a physician without a record of the balanced guidance they actually provided. What follows answers three questions: what to say, what to document, and where to refer.
TLDR: When a patient asks about stem cell banking, the physician should explain accurately that banking is the cryopreservation of the patient’s own fat-derived cells for potential future investigational use, that it is not a treatment, and that it is not FDA-approved for any condition; avoid any condition-specific benefit claim, which could raise an FTC substantiation issue; document the conversation (what was asked, what was said, any referral, the patient’s decision); and refer to a regenerative medicine specialist or the relevant condition specialist. Banking discussions are HIPAA-covered records. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical or legal advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
The instinct when caught off guard by a patient question is to answer reassuringly, and that instinct is exactly where the compliance risk lives. A casual “yes, that could help your knee” is a condition-specific benefit claim, and in a clinical context it carries the same substantiation expectation as any health claim. The safer and more useful posture is to give an accurate overview, decline to make benefit claims, document the exchange, and refer. None of that requires the physician to be an expert in regenerative medicine; it requires a disciplined, documented response.
Why This Conversation Has Compliance Implications
Stem cell banking and therapy span a complex regulatory space, parts FDA-regulated, parts state-law-governed, parts purely investigational, so an offhand answer can stray into territory the physician did not intend. A physician who makes an unsubstantiated claim about banking or stem cell therapy in a clinical context, even verbally, can create an FTC substantiation problem, because the agency’s standard for health claims applies to claims made in the course of offering or recommending a service. A physician who dismisses the question without documenting it loses the record showing that balanced, informed guidance was given. And HIPAA applies to banking-related discussions as to any clinical discussion. The exchange is a clinical event with documentation and compliance implications, not a casual aside.
What the Physician Should Know Before the Conversation
A general practitioner fielding this question needs only a working understanding, not specialist depth: that adipose tissue banking is the cryopreservation of a patient’s own fat-derived cells for potential future use; that banking is not a treatment and does not cure, treat, or prevent any disease; that there is an active investigational trial pipeline for adipose-derived MSC therapies across several conditions; that several states (Florida, Utah, Wyoming, California, Nevada) have enacted frameworks for physician-performed stem cell therapy under specific conditions; and that the FDA has not approved any adipose banking service as a medical treatment. The patient-demand context is covered in why patients are asking about banking, and the broader case in why physicians add banking.
A Compliant Response Framework
| Patient question | Compliant response | What not to say |
|---|---|---|
| What is stem cell banking? | Cryopreservation of your own fat-derived cells for potential future use in investigational therapies or trials; it is not a treatment. | “It’s a way to cure [disease]” or “it guarantees future treatment” |
| Will banking help my condition? | Banking does not treat your condition; it preserves tissue that may be relevant if future therapies or trials become available. | “Yes, it can help with [condition]” or any condition-specific benefit claim |
| Is it FDA-approved? | The banking procedure does not carry FDA approval as a treatment, and clinical use of stem cells is investigational for most conditions. | “Yes, it’s approved” or “it’s FDA-cleared” |
| Should I do it? | That is a decision with a regenerative medicine specialist; I can refer you. Factors include age, health status, condition, and trial eligibility. | A specific treatment recommendation without specialist evaluation |
| Is it safe? | The harvest is a minor outpatient procedure carrying the usual risks of infection, bruising, and bleeding; the long-term use of banked cells is investigational and cannot be fully characterized. | Any claim of zero risk or absolute safety |
The substantiation standard underlying the “what not to say” column is the FTC’s, examined further in the discussion of the FTC enforcement action against unsupported stem cell marketing.
What the Physician Must Document
Every banking conversation should generate a chart entry capturing the date and time; a brief description of what the patient asked; a brief description of what the physician said, including the information conveyed about the investigational nature of stem cell therapy; whether a referral was provided and to whom; the patient’s stated interest level or decision; and any written materials given. The reason is concrete: if a patient later claims the physician said banking would treat their disease, the contemporaneous chart entry showing balanced, accurate information is the physician’s primary defense.
When and How to Refer
A general practitioner is not expected to be the expert, only to refer appropriately. Reasonable referral options include a physician at a practice offering banking services, a regenerative medicine specialist, or a specialist in the patient’s condition familiar with the relevant trial pipeline. Where the patient has a serious condition with an active pipeline, ALS, MSA, Crohn’s perianal fistula, heart failure, or chronic TBI, a referral to the relevant specialist with a note that active trials exist is appropriate. Physicians can orient themselves to that pipeline through the guide on finding legitimate clinical trials.
A Charting Template
A model entry a physician can adapt: “Patient inquired about stem cell banking during [visit type] on [date]. I provided an overview of adipose tissue banking as the cryopreservation of autologous fat-derived cells for potential future use in investigational therapies. I advised that banking is not an FDA-approved treatment for any condition and does not guarantee access to or benefit from any future therapy. I advised that active clinical trials exist for [condition if applicable] and that a referral to [specialist type] may be appropriate. Patient [expressed interest / requested more information / declined further discussion]. I provided [written materials / referral / no additional materials] at this time.”
Physician Charting Checklist
- Date and time of the conversation documented.
- Patient’s question or concern documented.
- Information provided documented, balanced and free of unsubstantiated claims.
- Investigational nature of stem cell therapy communicated and documented.
- Referral provided or declined documented.
- Any written materials given documented.
- Chart entry completed before the end of the visit day.
Frequently Asked Questions
Can a casual verbal answer really create a compliance problem?
It can. A condition-specific benefit claim made in a clinical context, even verbally, carries an FTC substantiation expectation. The safer posture is an accurate overview without benefit claims, followed by documentation and referral.
What is the single most important thing to document?
That balanced, accurate information was provided, specifically that banking is not an approved treatment and does not guarantee benefit. That contemporaneous note is the physician’s primary defense if the conversation is later mischaracterized.
Does a primary care physician need to be an expert to handle this?
No. The expectation is an accurate overview, no benefit claims, documentation, and an appropriate referral, not specialist-level knowledge of regenerative medicine.
Key Takeaways
When a patient asks about stem cell banking, the physician’s job is to keep the conversation compliant, documented, and appropriately referred, not to sell banking. The compliant answer describes banking accurately as investigational tissue preservation, states plainly that it is not a treatment and not FDA-approved, and avoids any condition-specific benefit claim, which in a clinical context carries an FTC substantiation expectation. The conversation should be charted, what was asked, what was said, any referral, and the patient’s decision, because that record is the physician’s defense if the exchange is later mischaracterized. Serious conditions with active pipelines warrant referral to the relevant specialist. Banking remains a preservation decision separate from therapy, with no guarantee of future benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians who want a reliable place to refer patients with banking questions can contact Save My Fat for the preservation-side details.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
